Live Analyst Rating Changes 25553 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Madison Elsaadi
BR

Madison Elsaadi

B. Riley Securities
Wall Street Analyst
★★★★☆
#802
on 13Foresight · ranked by our own returns
50%
Success Rate
+9.8%
Average Return
12 of 24 calls profitable · +72.9% vs benchmark
S&P 500 (SPY)
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 50% of Madison Elsaadi's ratings turned a profit when each position was held for 1 year — averaging +9.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

38 Buy 1 Hold 0 Sell
Madison's Stock Coverage 12 ratings · 2026-08-18
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
VNDA
Vanda
 Aug 10, 2026 BUY Strong Buy
+281.2% avg upside
13 analysts
$12.00
128.15% Upside
 +3.8% ·
CMPS
COMPASS Pathways
 Aug 06, 2026 BUY Strong Buy
+62.2% avg upside
20 analysts
$22.00
60.33% Upside
 -0.7% ·
ARWR
Arrowhead Pharmaceuticals
 Aug 05, 2026 BUY Strong Buy
-15.2% avg upside
27 analysts
$123.00
38.77% Upside
 -0.3% ·
CAPR
Capricor Therapeutics
 Jul 31, 2026 HOLD Buy
+136.4% avg upside
12 analysts
$5.00
32.86% Downside
 +72.7% ·
WVE
Wave Life Sciences
 Jul 31, 2026 BUY Strong Buy
+308.0% avg upside
28 analysts
$22.00
332.32% Upside
 -1.8% ·
SPRB
Spruce Biosciences
 Jul 13, 2026 BUY Strong Buy
+98.7% avg upside
15 analysts
$160.00
202.38% Upside
 +8.8% ·
ETON
Eton Pharmaceuticals
 Jun 25, 2026 BUY Strong Buy
-38.4% avg upside
9 analysts
$40.00
35.28% Downside
 +77.2% ·
OVID
Ovid Therapeutics
 May 13, 2026 BUY Strong Buy
+75.7% avg upside
18 analysts
$5.00
72.95% Upside
 +1.1% ·
IRD
Opus Genetics
 Apr 30, 2026 BUY Strong Buy
+185.7% avg upside
25 analysts
$10.00
173.94% Upside
 -29.3% ·
FENC
Fennec Pharmaceuticals
 Feb 12, 2026 BUY Strong Buy
+44.0% avg upside
9 analysts
$16.00
35.21% Upside
 +42.9% ·
AXSM
Axsome Therapeutics
 Oct 01, 2025 BUY Strong Buy
+9.9% avg upside
29 analysts
$179.00
17.28% Downside
 +81.9% ·
AGEN
Agenus
 Jan 23, 2025 BUY Strong Buy
+23.1% avg upside
18 analysts
$11.00
53.87% Upside
 -13.8% ·
🔒 7 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Madison Elsaadi — Frequently Asked Questions
How accurate are Madison Elsaadi's stock ratings?
Based on the calls 13Foresight could measure, about 50% of Madison's ratings were profitable over a one-year hold, with an average return of +9.7% per rating, or +72.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Madison ranked on 13Foresight?
Madison Elsaadi is currently ranked #802 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Madison cover?
Madison most recently has ratings on VNDA, CMPS, ARWR, CAPR, WVE, SPRB, ETON, OVID, IRD, FENC, AXSM, AGEN. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.